JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB21844

FITC Anti-CD22 antibody [IS7]

Be the first to review this product! Submit a review

|

(1 Publication)

Mouse Monoclonal CD22 antibody - conjugated to FITC. Suitable for Flow Cyt and reacts with Human samples. Cited in 1 publication. Immunogen corresponding to Cell preparation containing CD22 protein.

View Alternative Names

CD22, SIGLEC2, B-cell receptor CD22, B-lymphocyte cell adhesion molecule, Sialic acid-binding Ig-like lectin 2, T-cell surface antigen Leu-14, BL-CAM, Siglec-2

1 Images
Flow Cytometry - FITC Anti-CD22 antibody [IS7] (AB21844)
  • Flow Cyt

Unknown

Flow Cytometry - FITC Anti-CD22 antibody [IS7] (AB21844)

Overlay histogram showing peripheral blood lymphocytes stained with ab21844 (red line). The cells incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions. The cells were then incubated with the antibody (ab21844, 0.5 μg/1x106 cells) for 30 min at 22°C. Isotype control antibody (black line) was mouse IgG1 FITC (2 μg/1x106 cells ) for 30 min at 22°C. Acquisition of >5,000 events was performed.

Key facts

Host species

Mouse

Clonality

Monoclonal

Clone number

IS7

Isotype

IgG1

Conjugation

FITC

Excitation/Emission

Ex: 495nm, Em: 519nm

Carrier free

No

Reacts with

Human

Applications

Flow Cyt

applications

Immunogen

Cell preparation containing CD22 protein. The exact immunogen used to generate this antibody is proprietary information.

P20273

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Species", "Dilution Info", "Notes"], "tabs": { "all-applications": {"fullname" : "All Applications", "shortname": "All Applications"}, "FlowCyt" : {"fullname" : "Flow Cytometry", "shortname":"Flow Cyt"} }, "product-promise": { "all": "all", "testedAndGuaranteed": "tested", "guaranteed": "expected", "predicted": "predicted", "notRecommended": "not-recommended" } }, "values": { "Human": { "FlowCyt-species-checked": "testedAndGuaranteed", "FlowCyt-species-dilution-info": "4.15 µL for 10^6 Cells", "FlowCyt-species-notes": "<p><a href='/en-us/products/primary-antibodies/fitc-mouse-igg1-b11-6-isotype-control-ab91356'>ab91356</a> - Mouse monoclonal IgG1, is suitable for use as an isotype control with this antibody.</p>" }, "Primates": { "FlowCyt-species-checked": "predicted", "FlowCyt-species-dilution-info": "", "FlowCyt-species-notes": "" } } }

Product details

The purified antibody is conjugated with Fluorescein isothiocyanate (FITC) under optimum conditions. The reagent is free of unconjugated FITC and adjusted for direct use. No reconstitution is necessary.

Properties and storage information

Form
Liquid
Purification technique
Affinity purification Protein G
Storage buffer
pH: 7.4 Preservative: 0.097% Sodium azide Constituents: BSA, PBS
Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
+4°C
Appropriate long-term storage conditions
+4°C

Supplementary information

This supplementary information is collated from multiple sources and compiled automatically.

CD22 also known as Siglec-2 or B-lymphocyte cell adhesion molecule (BL-CAM) is a transmembrane protein with a mass of around 140 kDa. It is selectively expressed on the surface of mature B cells and some immature B cells. This protein plays an important role in the immune system particularly in the regulation of B cell function. CD22 functions by modulating signal transduction processes through its cytoplasmic domain which contains immunoreceptor tyrosine-based inhibitory motifs (ITIMs).
Biological function summary

CD22 acts mainly as a negative regulator of B cell receptor (BCR) signaling. It is part of a complex that interacts with the BCR and other accessory molecules. CD22 helps maintain B cell tolerance by inhibiting overactive signaling and preventing autoimmune responses. By binding to sialic acid-containing glycans CD22 modulates interactions between B cells and other cells aiding in the maintenance of immune homeostasis.

Pathways

CD22 plays a critical role in the BCR signaling pathway and the regulation of phosphatidylinositol 3-kinase (PI3K) signaling. It works together with proteins like CD19 and SHP-1 that are key components of these pathways. By influencing these signaling cascades CD22 contributes to the modulation of B cell activation proliferation and apoptosis ensuring proper functioning of the immune response.

CD22 is associated with autoimmune conditions and hematological malignancies such as hairy cell leukemia (HCL). Therapeutic approaches targeting CD22 such as anti-CD22 antibodies are being explored for treating these diseases. CD22's role in these conditions is connected with proteins involved in the autoimmune pathways or cancer development offering potential therapeutic targets for intervention.

Product protocols

For this product, it's our understanding that no specific protocols are required. You can visit:

Target data

Most highly expressed siglec (sialic acid-binding immunoglobulin-like lectin) on B-cells that plays a role in various aspects of B-cell biology including differentiation, antigen presentation, and trafficking to bone marrow (PubMed : 34330755, PubMed : 8627166). Binds to alpha 2,6-linked sialic acid residues of surface molecules such as CD22 itself, CD45 and IgM in a cis configuration. Can also bind to ligands on other cells as an adhesion molecule in a trans configuration (PubMed : 20172905). Acts as an inhibitory coreceptor on the surface of B-cells and inhibits B-cell receptor induced signaling, characterized by inhibition of the calcium mobilization and cellular activation. Mechanistically, the immunoreceptor tyrosine-based inhibitory motif domain is phosphorylated by the Src kinase LYN, which in turn leads to the recruitment of the protein tyrosine phosphatase 1/PTPN6, leading to the negative regulation of BCR signaling (PubMed : 8627166). If this negative signaling from is of sufficient strength, apoptosis of the B-cell can be induced (PubMed : 20516366).
See full target information CD22

Publications (1)

Recent publications for all applications. Explore the full list and refine your search

Oncology letters 27:14 PubMed38028179

2023

CBX7 is involved in the progression of cervical cancer through the ITGβ3/TGFβ1/AKT pathway.

Applications

Unspecified application

Species

Unspecified reactive species

Ping Tian,Jinglan Deng,Cailing Ma,Ainipa Miershali,Gulikezi Maimaitirexiati,Qi Yan,Yating Liu,Hatimihan Maimaiti,Yuting Li,Changhui Zhou,Jingqin Ren,Lu Ding,Rong Li
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com